1383822-31-8Relevant articles and documents
Isoxazole derivative, pharmaceutical composition containing isoxazole derivative, and preparation method and application thereof
-
, (2021/05/19)
The present invention belongs to the field of pharmaceutical chemistry, and generally relates to an isoxazole derivative, and stereoisomers, tautomers, polymorphs, solvates (such as hydrates), esters, metabolites, N-oxides and chemically protected forms and prodrugs thereof, or pharmaceutically acceptable salts thereof. The invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound and the pharmaceutical composition in treating diseases or conditions mediated by farnesoid X receptor (FXR).
ISOXAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
-
Sheet 0117; 0129; 0136, (2020/11/26)
The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.
COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES
-
Page/Page column 265; 267, (2020/12/07)
In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.